ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / AGMB / financials
FENC (37) TECX (30) CCCC (28) TRXB (47) ⌘ Pro Terminal →

AgomAb Therapeutics NV (AGMB) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$7.49 -5.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.40

AgomAb Therapeutics NV (AGMB) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $391.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AGMB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AGMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, AgomAb Therapeutics NV (NASDAQ: AGMB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $7.49 (-5.79% 1D, market cap $391.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AGMB ranks #408 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AGMB compare to FENC and TECX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AGMB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, FENC (Fennec Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -25.9%, cap $383.6M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $400.8M). Among the 5-stock peer group, AGMB leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AGMB?
▼

For AgomAb Therapeutics NV (AGMB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #408 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.40 (-1.23%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.9% Base Target
$19 Bull$7 Base$6 Bear
📬 FREE AGMB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AGMB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY AGMB SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($11.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
53
Grade C-$9.09-9.5% Next Q
Q2 (-2Q)
50
Grade C-$8.23+4.1% Next Q
Q3 (-1Q)
48
Grade D$8.57-12.6% Next Q
Current
45
Grade D$7.49-6.3% Hist 90D α
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AGMB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AGMB currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.81) and Max Pain ($7.86) forces dealer call-delta covering toward $18.71.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AGMB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AGMB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How AGMB Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$11.0M (0.3% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $1.08B (27%)OpEx (R&D/SG&A) $998.4MNet Profit$865.3M (21.6%)Tax/Other $216.3M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AGMB)

  • ✓Walkthrough of AGMB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AGMB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.15%🛡️ HOLDING TREND SUPPORT
2026-11-02O $7.96H $7.96L $7.49C $7.49VOL 575.4K
RES: $15.45SUP: $6.72SMA50: $10.81SMA200: $12.08
$18.60$15.35$12.10$8.85$5.60RES $15.45SUP $6.72$7.492026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AGMB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AGMB Butterfly Map → + Track AGMB →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AGMB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AGMB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AGMB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AGMB)

Health Care Rank #408 of 1016 ⚔️ FENC vs AGMB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AGMB vs. FENC, TECX, CCCC, TRXB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AgomAb Therapeutics NV (AGMB) ranks #408 by composite RQD confidence (45/100, grade D) and #483 by equity capitalization ($391.5M). Within this direct 5-issuer industry benchmark cohort, AGMB leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. TRXB currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with AGMB at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AGMB ACTIVE
AgomAb Therapeutics NV
D 45/100 — — — -5.79% $391.5M Benchmark Subject
FENC
Fennec Pharmaceuticals Inc.
D- 37/100 — — -25.9% -6.48% $383.6M /fenc-vs-agmb →
TECX
Tectonic Therapeutic Inc.
E 30/100 — — -35.0% -3.51% $400.8M /tecx-vs-agmb →
CCCC
C4 Therapeutics Inc.
E 28/100 — — -35.0% +2.12% $406.0M /cccc-vs-agmb →
TRXB
TRex Bio Inc.
D 47/100 — — — +1.63% $371.1M /trxb-vs-agmb →

2. AGMB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

AgomAb Therapeutics NV (AGMB) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $391.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. AGMB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AGMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, AgomAb Therapeutics NV (NASDAQ: AGMB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $7.49 (-5.79% 1D, market cap $391.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AGMB ranks #408 in composite RQD confidence.

How does AGMB compare to FENC and TECX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AGMB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, FENC (Fennec Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -25.9%, cap $383.6M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $400.8M). Among the 5-stock peer group, AGMB leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AGMB?

For AgomAb Therapeutics NV (AGMB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #408 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AGMB trading relative to its 50-day, 200-day, and 52-week technical levels?

AGMB last traded at $7.49 (-5.79% on volume of 197,838 shares), positioning the stock -30.71% below its 50-day simple moving average ($10.81) and -38.00% below its 200-day simple moving average ($12.08). Across its 52-week range of $6.61 to $17.82, AGMB sits at the 7.9% percentile with a 14-day RSI of 36.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.55 to $8.43).

AGMB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is AgomAb Therapeutics NV (AGMB)?

In Trailing 12 Months, AGMB converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $11.0M in free cash flow (0.3% FCF margin).

Direct Sub-Reports: AGMB RQD Cockpit AGMB 12M Forecast AGMB Earnings & Move AGMB Dividends & DRIP AGMB Insiders & 13F AGMB Whale Options AGMB Profit Sankey AGMB News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AGMB — AgomAb Therapeutics NV: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:16:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AGMB carries an RQD Score of 45, a letter grade of D, and the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 3/20 (institutional accumulation and options positioning); Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillar is institutional flow at 3/20, and the cash-generation pillar is also weak given the reported 0% ROIC and 0% FCF yield. The balance-sheet pillar is the strongest of the five, though still only moderate. For a prospective investor, the rating points to limited current evidence of cash-based value support, with the balance sheet providing the most stability. Any upside case would depend on developments not captured in the reported cash-generation metrics. This is an analytical summary, not personalized financial advice.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, the most prominent items are as follows. A Yahoo Finance stock forecast and price target item is flagged as a market wire item. A GuruFocus item reports a director purchase of 10,000 shares. A Stock Titan item reports a director buying 5,000 shares twice. A Globe and Mail item covers analyst bullishness on healthcare names, including AGMB and other tickers, and is the only item tagged as a catalyst. An Investing.com Canada item covers a Form 4 filing by David R. Epstein, and a Quiver Quantitative item covers insider stock purchases dated October 22, 2026. Taken together, the news flow is dominated by insider purchase disclosures. The Butterfly Supply-Chain Graph reports no supply chain, no butterfly links, and no proprietary signals. Risk watch items per the source data are limited to the absence of reported profitability and the absence of analyst coverage.

Open Questions

  • What are AGMB's reported revenue, operating income, and net income across recent periods, given that the financials section contains no data?
  • What is the company's product pipeline and revenue model, given that the business description is not available in source data?
  • What is the basis for the reported 0% ROIC and 0% FCF yield, and what are the company's cash and debt balances?
  • What analyst coverage and consensus price targets exist, given that the analyst data section is empty?
  • What institutional (13F) and Congressional holdings exist, given that the holders section is empty?

AGMB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AgomAb Therapeutics NV (AGMB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AGMB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AGMB Bull vs. Bear Conversation Board — What's Your Call at $7.49?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AGMB 🐻 67% BEARISH CONVICTION
1. Pick Your Side on AGMB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $7.00 (-11.9%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AGMB (D • RQD 45/100) a Buy at $7.95?

Welcome to the AGMB (AgomAb Therapeutics NV) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $6.20 (-22.0%)
Spot @ $7.95

Pump the brakes on AGMB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AGMB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless AgomAb Therapeutics NV expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $9.94 (+25.0%)
Spot @ $7.95

AGMB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AGMB, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $7.95 (52-wk range $6.61 - $17.82), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%